NCT05238883 2025-11-21
A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors
HiFiBiO Therapeutics
Phase 1 Active not recruiting
Clinical Trials
7 trialsNCT04693234 2025-04-27
AdvanTIG-202: Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Previously Treated Recurrent or Metastatic Cervical Cancer
BeiGene
Phase 2 Completed
NCT05588219 2023-11-24
Tislelizumab Combined With Concurrent Chemoradiotherapy for Locally Advanced Cervical Cancer
First Affiliated Hospital of Guangxi Medical University
Phase 2 Unknown
NCT06039891 2023-09-15
Nimotuzumab Plus Tislelizumab for Recurrent and Metastatic Cervical Cancer
Peking Union Medical College Hospital
Phase 2 Not yet recruiting
NCT05614453 2023-06-29
ITTACC
Australia New Zealand Gynaecological Oncology Group
Phase 2 Withdrawn
NCT05247619 2022-07-15
A Clinical Study to Explore the Efficacy and Safety of Tislelizumab in Combination With Bevacizumab and Chemotherapy in Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
Zhejiang Cancer Hospital
Phase 2 Unknown
NCT05310383 2022-04-11
Tislelizumab and Radiotherapy for Recurrent Cervical Cancer
Peking Union Medical College Hospital
Phase 2 Unknown